Guenter Janhofer - 23 Oct 2023 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role: Chief Scientific Officer
Signature: /s/ Brendan Hannah, Attorney-in-Fact for Guenter Janhofer, M.D., Ph.D.
Issuer symbol: QNCX
Transactions as of: 23 Oct 2023
Net transactions value: $0
Form type: 4
Filing time: 24 Oct 2023, 19:42:07 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QNCX	Employee Stock Option (right to buy)	Award	$0	+300,000		$0.000000	300,000	23 Oct 2023	Common Stock	300,000	$0.9900	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-five percent of the shares subject to the stock option vests on the first anniversary of the grant date of October 23, 2023, and the remainder vests in 36 equal monthly installments thereafter for the following three years, subject to the Reporting Person's continuous service as the officer of the Issuer as of each such date.